Spero Therapeutics, Inc. (Spero), A Multi-Asset Clinical-Stage Biopharmaceutical Company, Announced The Closing Of Its Previously Announced Exclusive License Agreement With Glaxosmithkline Intellectual Property (No. 3) Limited (Gsk) For Tebipenem Hbr, An Investigational Drug Being Developed As The Potentially First Oral Carbapenem Antibiotic For The Treatment Of Complicated Urinary Tract Infections (Cuti), Including Pyelonephritis, Caused By Certain Bacteria.Pursuant To The License Agreement, Spero Will Be Receiving A $66 Million Upfront Payment From Gsk And Is Eligible To Receive Up To $525 Million In Development, Sales, And Commercial Milestones Payments, As Well As Low-Single Digit To Low-Double Digit Tiered Royalties On Net Product Sales. In Exchange, Gsk Has Been Granted An Exclusive License To Develop And Commercialize Tebipenem Pivoxil And Tebipenem Pivoxil Hbr In All Territories, Except Japan, And Certain Other Asian Countries, Territories Which Will Be Retained By Spero Partner, Meiji Seika. In Connection With Closing, Pursuant To The License Agreement And A Previously Announced Stock Purchase Agreement Between The Parties, An Affiliate Of Gsk Has Purchased 7,450,000 Shares Of Spero
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!